Cilastatin

• Description :

  Cilastatin (MK0791) is a reversible, competitive renal dehydropeptidase I inhibitor with an IC50 of 0.1 μM. Cilastatin inhibits the bacterial metallob-lactamase enzyme CphA with an IC50 of 178 μM. Cilastatin is an antibacterial adjunct[1][2][3].

• Product Name Alternative :

  MK0791

• UNSPSC :

  12352211

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  Antibiotic; Bacterial

• Type :

  Reference compound

• Related Pathways :

  Anti-infection

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Infection

• Assay Protocol :

  https://www.medchemexpress.com/Cilastatin.html

• Concentration :

  10mM

• Purity :

  99.91

• Solubility :

  1M NaOH : 100 mg/mL (ultrasonic; adjust pH to 12 with NaOH) |DMSO : 100 mg/mL (ultrasonic) |H2O : 5 mg/mL (ultrasonic; warming; heat to 60°C)

• Smiles :

  O=C(O)/C(NC([C@@H]1C(C)(C)C1)=O)=C/CCCCSC[C@H](N)C(O)=O

• Molecular Formula :

  C16H26N2O5S

• Molecular Weight :

  358.45

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]The renal membrane dipeptidase (dehydropeptidase I) inhibitor, cilastatin, inhibits the bacterialmetallo-beta-lactamase enzyme CphA. Antimicrob Agents Chemother. 1995 Jul;39 (7) :1629-31.|[2]Blanca Humanes, et al. Protective Effects of Cilastatin Against Vancomycin-Induced Nephrotoxicity. Biomed Res Int. 2015;2015:704382.|[3]P J Petersen, et al. In Vitro and in Vivo Activities of LJC10,627, a New Carbapenem With Stability to Dehydropeptidase I. Antimicrob Agents Chemother. 1991 Jan;35 (1) :203-7.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Launched

• Isoform :

  β-lactam

• CAS Number :

  [82009-34-5]